Therefore, regarding the role of GluN2A in the rapid antidepressant-like effect of ketamine, specific inhibition of GluN2A NMDAR may be developed to eliminate the side effects of ketamine and improve safe and effective innovative treatments for depression. The gene discussed is GRIN2A; the disease is depressive disorder.